Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W.P. Castelli, K. Anderson.
Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. A population at risk.
Am J Med, 80 (1986), pp. 23-32
[2.]
G. Assmann, H. Schulte.
The prospective cardiovascular Munster (PROCAM study): prevalence of hyperlipidemia in persons with hypertension and or diabetes mellitus and the relationship to coronary heart disease.
Am Heart J, 116 (1988), pp. 1713-1724
[3.]
P. Aranda, J.M. Aranda, J. Carmona, S. Núñez.
Relaciones entre colesterol y presión arterial en el estudio Málaga 86. ¿Algo más que una asociación casual?.
Rev Clin Esp, 187 (1990), pp. 13-17
[4.]
A. Marín, P. Cía, F. Adán, A. Martínez-Berganza, M.P. Samperiz, M. Rivas, et al.
Perfil clínico y metabólico en hipertensos remitidos a una Unidad de Hipertensión.
And Med Intern (Madrid, 9 (1992), pp. 23
[5.]
S.W. MacMahon, G.J. MacDonald, R.B. Blackert.
Plasma lipoprotein levels in treated and untreated hypertensive men and women.
Arteriosclerosis, 5 (1985), pp. 391-396
[6.]
H. Pardell, P. Armario, R. Hernández.
Pathogenesis and epidemiology of arterial hypertension.
Drugs, 56 (1998), pp. 1-10
[7.]
M. Kasterimen, J. Toumilehto, E. Vartiainen, P. Jousilahti, J. Sundvall, P. Puska, et al.
Trends in lipid levels and hypercholesterolemia in hypertensive and normotensive finnish adults from 1982 to 1997.
J Intern Med, 247 (2000), pp. 53-62
[8.]
C. González-Villalpando, M.P. Stern, S.M. Haffner, M.E. González Villalpando, S. Gaskill, D. Rivera Martínez.
Prevalence of hypertension in a Mexican population according to the Sixth report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure.
J Cardiovasc Risk, 6 (1999), pp. 177-181
[9.]
K.H. Bonaa, D.S. Thelle.
Association between blood pressure and serum lipids in a population. The Tromso Study.
Circulation, 83 (1991), pp. 1305-1313
[10.]
F. Facchini, Y.D. Ida Chen, C. Clinkingbeard, J. Jeppesen, G.M. Reaven.
Insulin resistance hyperinsulinemia and dyslipemia in obese individuals with a family history of hypertension.
Am J Hypertens, 5 (1992), pp. 694-699
[11.]
R. García Closas, L. Serra Majem, P. Chacón Castro, M. Olmos Castellvell, L. Rivas Barba.
Salleras Sanmartí L y Grupo de Investigación sobre Evaluación del Estado Nutricional de la Población Catalana: Evaluación Bioquímica. Distribución de la concentración de lípidos séricos en una muestra representativa de la población adulta de Cataluña.
Med Clin (Barc), 113 (1999), pp. 6-12
[12.]
F.J. Nieto, J. Alonso, L.E. Chaanbles, M. Zhong, M. Ceraso, F.J. Romm, et al.
Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities Study.
Arch Intern Med, 155 (1995), pp. 677-684
[13.]
R.M. Pieper, D.K. Arnett, P.G. McGovern, E. Shaliar, H. Blacburn, R.V. Luepker.
Trends in cholesterol knowledge and screening and hypercholesterolemia. Awareness and treatment, 1980-1992.
Arch Intern Med, 157 (1997), pp. 2326-2332
[14.]
T.R. Pedersen, J. Kjekshus, K. Pyórala, A.G. Olsson, T.J. Cook, T.A. Niusliner, et al.
Effect of symvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (45.
Am J Cardiol, 81 (1998), pp. 333-335
[15.]
J.F. Plehn, B.R. Davis, F.M. Sacks, J.L. Rouleau, M.A. Pfefer, V. Bernstein, et al.
Reduction of istroke Incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study.
Circulation, 99 (1999), pp. 216-223
[16.]
P.B. Gorelick, R.L. Sacco, D.B. Smith, M. Alberts, L. Mustone-Alexander, D. Rader, et al.
Prevention of a first stroke. A review of Guidelines and a Multidisciplinary Cosensus Staternent from the National Stroke Association.
JAMA, 28 (1999), pp. 1112-1120
[17.]
P. Cía Gómez, Duarte J Mozota, P. Cía Blasco, A. Marín Ballvé.
Alteraciones metabólicas en la hipertensión arterial esencial.
Hipertension, 15 (1998), pp. 88-94
[18.]
R.R. Williams, S.G. Hunt, P.N. Hopidris, B.M. Stults, L.L. Wu, S.J. Hadstedt, et al.
Familial dyslipidemic hypertension: evidence frorn 58 Utah farnilies for a syndrome present in approximately 15% of patients with essential hypertension.
JAMA, 259 (1988), pp. 3579-3586
[19.]
S. Julius, K. Jamerson.
Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-an-egg’ question.
J Hypertens, l2 (1994), pp. 495-500
[20.]
P. Armario, R. Hernández del Rey, M. Martin-Baranera, G. Torres, J. Ruigómez, U. Pardell.
Factors related to dyslipidaemia in untreated rnild hypertension. Hospitalet Study in Mild Hypertension.
Am J Hypertens, 10 (1997), pp. 211
[21.]
P. Armario, R. Hernández del Rey, M. Martin-Baranera, G. Torres, H. Pardell.
Prevalence and related factors to hypoalphalipoproteinemia in untreated mild hypertension.
Atherosclerosis, 134 (1997), pp. 95
[22.]
S. Julius, K. Jamerson, A. Niejia, L. Krause, N. Schork, K. Jones.
The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study.
JAMA, 264 (1990), pp. 354-358
[23.]
1999 World Health Orgatzation-International Society of Hypertension. Guidelines for the management of hypertension: Guidelines Subcommittee.
J Hypertens, 17 (1999), pp. 151-183
[24.]
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI).
Arch Intern Med, 157 (1997), pp. 2413-2446
[25.]
J.I. Cleeman.
Detection and evaluation of dyslipoproteinemias.
Endocrinol Met Clin N Am, 27 (1998), pp. 597-611
[26.]
W.T. Donahoo, L.A. Kosmilci, R.H. Eckel.
Drugs causing dyslipoproteinemia.
Endocrinol Met Clin N Am, 27 (1998), pp. 677-697
[27.]
J.A. Gómez Gerique, M.T. Montoya.
Estandarización de Ia medición de lípidos y lipoproteínas.
Clin Invest Arteriosclerosis, 11 (1999), pp. 28-47
[28.]
Sociedad Española de Arteriosclerosis, Sociedad Española de Medicina Interna y Liga Española para la Lucha contra la Hipertensi6n Arterial. Recomendaciones para la prevención primaria de la enfermedad cardiovascular.
Clin Invest Arteriosclerosis, 6 (1994), pp. 62-102
[29.]
R.B. Devereux, M.H. Alderman.
Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events.
Circulation, 88 (1993), pp. 1444-1455
[30.]
P. Armario, R. Hernández del Rey, P. Sánchez, M. Martín-Baranera, G. Torres, J. Juliá, H. Pardell.
Determinants of left ventricular mass in untreated mild hypertensive subjects. Hospitalet Study in NLId Hypertension.
Am J Hypertens, 12 (1999), pp. 1084-1090
[31.]
N. Reichek, R.B. Devereux.
Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings.
Circulation, 63 (1981), pp. 1391-1398
[32.]
D. Levy, K.N. Anderson, D.D. Savage, W.B. Kannel, J.C. Christiasen, W.P. Castelli.
Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Study.
Ann Intern Med, 108 (1988), pp. 7-13
[33.]
M.J. Koren, R.B. Devereux, P.N. Casale, D.D. Savage, J.H. Laragh.
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.
Ann Intern Med, 114 (1991), pp. 345-352
[34.]
P. Armario, R. Hernández del Rey, H. Pardell.
Microalbuminuria. Prevalencia y su significado en la Hipertensión.
Hipertension, 16 (1999), pp. 251-254
[35.]
D.H. O’Leary, J.F. Polak, R.A. Krormal, T.A. Manolio, C.L. Burke, S.K. Wolfson, et al.
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults.
N Engl J Med, 340 (1999), pp. 14-22
[36.]
R.E. Zierler, R.O. Bergelin, N.L. Polissar, K.W. Beach, M.T. Caps, K. Cantwell, et al.
Carotid and lower extremity arterial disease in patients with renal artery atherosclerosis.
Arch Intern Med, 158 (1998), pp. 761-767
[37.]
J. Biller, W.M. Feinberg, J.E. Castaldo, A.D. Whitteniore, R.E. Harbaugh, R.J. Dempsey, et al.
Guidelines for carotid endarterectomy. A Statement for Healthcare Professionals from a Special Writing Group of the Stroke Council, American Heart Association.
Circulation, 97 (1998), pp. 501-509
[38.]
P.W. Wilson, W.B. Kannel, H. Silbershatz, R.B. D’Agostino.
Clustering of metabolic factors and coronary heart disease.
Arch Intern Med, 159 (1999), pp. 1104-1109
[39.]
G.S. Berenson, S.R. Srinivasan, W. Bao, V.P. III. Newman, R.E. Tracy, A.W. Wattigney.
for the Bogalusa Heart Study.
N Engl J Med, 338 (1998), pp. 1650-1656
[40.]
S.M. Grundy.
Primary Prevention of coronary heart disease. Integrating risk assesment with intervention.
Circulation, 100 (1999), pp. 988-998
[41.]
D. Wood, C. De Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä.
together with members of the Task Force. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.
J Hypertens, 16 (1998), pp. 1407-1414
[42.]
National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Circulation, 89 (1994), pp. 1329-1445
[43.]
J. Stamler.
Epidemiologyc findings on body mass and blood pressure in adults.
Ann Epidemiol, 1 (1991), pp. 347-362
[44.]
D.G. Bao, T.A. Mori, V. Burke, I.B. Puddey, L.J. Beilin.
Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives.
Hypertension, 32 (1998), pp. 710-717
[45.]
M.R. Law.
Epidemiological evidence on salt and blood pressure.
Am J Hypertens, 10 (1997), pp. 42-45
[46.]
R. Stamler.
Implications of the INTERSALT study.
Hypertension, (1991), pp. 16-20
[48.]
I.B. Puddey, L.J. Beilin, V. Rakic.
Alcohol, hypertension and the cardiovascular system: a critical appraisal.
Addiction Biol, 2 (1997), pp. 159-170
[49.]
R. Infante.
Polifenoles del vino y oxidabilidad de las lipoproteínas. ¿Blanco o tinto?.
Clin Invest Arterioscler, 9 (1999), pp. 19-22
[50.]
F.S. Facchini, C.B. Hollenbech, J. Jeppesen, Y.D.C. Chen, G.M. Reaven.
Insulin resistance and cigarrette smoking.
Lancet, 339 (1992), pp. 1128-1130
[52.]
R.H. Fagard.
The role of exercise in blood pressure control: supportive evidence.
J Hypertens, 13 (1995), pp. 1223-1227
[53.]
G.L.R. Jennings.
Exercise and blood pressure: walk, run or swin?.
J Hypertens, (1997),
[54.]
T.L. Lindquist, L.J. Beilin, M.W. Knuiman.
Influence of lifestyle, coping and job stress on blood pressure in men and women.
Hypertension, 29 (1997), pp. 1-7
[55.]
T.G. Pickering, R.B. Devereux, G.D. James, W. Gerin, P. Landsbergis, P.L. Schnall, et al.
Environmental influences on blood pressure and the role of job strain.
J Hypertens, 5 (1996), pp. 179-185
[56.]
J.R.H. Grimm, A.S. Leon, D.B. Hunninghake, K. Lenz, P. Hannan.
Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hipertensive patients.
Ann Intern Med, 15 (1981), pp. 4-7
[57.]
G.M. Reaven.
Role of abnormalities of carbohydrate and lipoprotein metabolism in the pathogenesis and clinical course of hypertension.
J Cardiovascular Pharmacol, 15 (1990), pp. 4-7
[58.]
R.H. Grimm, J. Flack, A. Gregory, P.J. Elmer, J.D. Neaton, J.A. Cutler, et al.
Long-term effects on plasma lipids of diet and drugs to treat hypertension.
JAMA, 275 (1996), pp. 1549-1556
[59.]
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.
JAMA, 24 (1991), pp. 3255-3264
[60.]
R.H. Grimm.
Antihypertensive therapy: taking lipids into consideration.
Am Heart J, 122 (1991), pp. 910-918
[61.]
M.A. Weber.
Hypertension with concomitant conditions: the changing role of alfa-adrenoreceptor blockade.
Am Heart J, 121 (1991), pp. 716-723
[62.]
H.R. Superko, W.L. Kaskell, R.M. Krauss.
Association of lipoprotein subclass distribution with use of selective and non-selective betablocker medications in patients with coronary heart disease.
Arteriosclerosis, 101 (1993), pp. 1-8
[63.]
R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, K.A. Eberlein, et al.
Blood pressure, stroke, and coronary heart disease. Part 2, shortterm reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
Lancet, 335 (1990), pp. 827-838
[64.]
H.R. Black.
The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy.
J Cardiovasc Pharmacol, 15 (1990), pp. 26-38
[65.]
S.W. Rabkin.
Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment.
J Clin Pharmacol, 33 (1993), pp. 286-291
[66.]
B. Kiens, H. Lithell, K.J. Mikines, E.A. Richter.
Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relations to insulin action.
J Clin Invest, 84 (1989), pp. 1124-1129
[67.]
M. Laakso, V. Edelman, G. Brechtel, A.D. Baron.
Decrease effect of insulin to stimulate skeletal muscle blood flow in obese man.
J Clin Invest, 85 (1990), pp. 1844-1852
[68.]
L. Lind, H. Lithell.
Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia and hyperinsulinemia.
Am Heart J, 125 (1993), pp. 1494-1497
[69.]
T. Pollare, H.O. Lithell, I. Selinus, C. Berne.
Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.
Br Med J, 298 (1989), pp. 1152-1157
[70.]
H. Lithell, T. Pollare, B. Vessby.
Metabolic effects of pindolol and propranolol in a double-blid cross-over study in hypertensive patients.
Blood Pressure, 1 (1992), pp. 92-101
[71.]
A.L.M. Swislocki.
Impaired insulin clearance in essential hypertension.
J Hum Hypertens, 8 (1994), pp. 185-190
[72.]
A. Haenni, H. Lithell.
Treatment with a betablocker with alfa-2-agonism improves glucose and lipid metabolism in essential hypertension.
Metabolism, 43 (1994), pp. 455-461
[73.]
K. Malminiemi.
Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment.
Cardiovasc Drugs Ther, 9 (1995), pp. 295-304
[74.]
G. Feuerstein, T.L. Yue, R.R. Ruffolo.
Carvedilol update: a multiple action antihypertensive agent with antioxidant capacity and the potential for myocardial and vascular protection.
Drugs Today, 29 (1993), pp. 401-419
[75.]
J.L. Mehipertensión, L.M. López, L. Chen, O.E. Cox.
Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and the effects of celiprolol.
Am J Cardiol, 74 (1994), pp. 901-905
[76.]
P. Roesen, T. Ballhausen, W. Bloch, K. Addicks.
Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as an antioxidant.
Diabetologia, 38 (1995), pp. 1157-1168
[77.]
T. Pollare, H.O. Lithell, C. Berne.
A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.
N Engl J Med, 321: 6868-873 (1989),
[78.]
C. Berne, T. Pollare, H. Lithell.
Effects of antihypertensives on insulin sensitivity with special reference to ACE inhibitors.
Diabetes Care, 14 (1991), pp. 39-47
[79.]
A.V. Chobaina, C.C. Haudenchild, C. Nickerson, R. Drago.
Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.
Hypertension, 15 (1990), pp. 327-331
[80.]
J.S. Powell, J.P. Clozel, R.K.M. Muller.
Inhibitors of angiotensin converting enzyme prevent miointimal proliferation after vascular injury.
Science, 245 (1989), pp. 186-188
[81.]
H.R.I. Christensen, H. Nilesen, K.L. Christensen.
Long term hypotensive effects an angiotensin converting enzyme inhibitor in spontaneously hypertensive rats: is there a role for vascular structure?.
J Hypertens, 3 (1988), pp. 27-31
[82.]
E.M. Lonn, S. Yusuf, P. Jha, T.J. Montague, K.K. Teo, C.R. Bendict, B. Pitt.
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
Circulation, 90 (1994), pp. 2056-2069
[83.]
C.L. Jackson, R.C. Bush, D.E. Bowyer.
Inhibitory effects of calcium antagonists on ballon catheter induce arterial smooth muscle cell proliferation and lesion size.
Atheroesclerosis, 69 (1988), pp. 115-122
[84.]
P.D. Henry.
Calcium antagonists as antiatheroesclerotic agents.
Arteriosclerosis, 10 (1990), pp. 963-965
[85.]
T. Pollare, H.O. Lithell, I. Selinus, C. Berne.
Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension.
Diabetologia, 31 (1988), pp. 415-420
[86.]
R. Huuppnen, A. Lehtonen, M. Vähätalo.
Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
Eur J Clin Pharmacol, 43 (1992), pp. 365-368
[87.]
Grupos de Trabajo en Hipertension. Antagonistas de los receptores de la AII y protección integral del hipertenso. Sociedad Española de Hipertensión Liga Española para la Lucha contra la Hipertensión Arterial 1998
[88.]
V.J. Dzau, M. Mukoyama, R.E. Pratt.
Molecular biology of angiotensin receptors: target for drug research?.
J Hypertens, 12 (1994), pp. 1-5
[89.]
P. Bousquet, J. Feldman, J. Schwartz.
Central cardiovascular effects of alpha adrenergic drugs: differences between cathecolamines and imidazolines.
J Pharmacol Exp Ther, 230 (1984), pp. 232-236
[90.]
P. Ernsberger, T.H. Damon, L.M. Graff, S.G. Schafer, M.O. Christen.
Moxonidine a centrally acting antihypertensive agent, is a selective ligand for Imidazoline sites.
J Pharmacol Exp Ther, 264 (1993), pp. 172-182
[91.]
P. Rösen, R. Rösen.
The rationale for sympathetic modulation in NIDDM and the insulin resistance syndrome.
Rev Contemp Pharmacother, 9 (1998), pp. 429-439
[92.]
H.C. Jackson, I.J. Griffin, D.J. Nutt.
The effects of idazosan and other water alpha-2-adrenoceptor antagonists on food and water intake in the rat.
Br J Pharmacol, 104 (1991), pp. 2578-2620
[93.]
P. Rosen, P. Ohly, H. Gleichman.
Experimental benefit of moxonidine on glucose metabolism and insulin section in the fructose-fet rat.
J Hypertens, 15 (1997), pp. 31-38
[94.]
A. Chobanian.
Effects of beta blockers and other antihypertensive drugs on cardiovascular risk.
Am J Cardiol, 59 (1997), pp. 1
[95.]
Grupos de trabajo en Hipertensión. Combinaciones de antihipertensivos en el tratamiento de la hipertensión arterial. Sociedad Española de Hipertensión Arterial. Madrid: Liga Española para la lucha contra la Hipertensión arterial 1997
[96.]
Documento de Consenso. Recomendaciones para el control de la colesterolemia en España.
Clin Invest Arterioscler, 12 (2000), pp. 307-317
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.